Status:
COMPLETED
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
Lead Sponsor:
SWOG Cancer Research Network
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Multiple Myeloma
Plasma Cell Myeloma
Eligibility:
All Genders
Brief Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with monoclonal gammopathy of undetermined significance, multiple myeloma, or plasmacytoma may help doctors learn m...
Detailed Description
OBJECTIVES: * Establish a serum, cell, and bone marrow tissue bank of prospectively collected samples from patients with monoclonal gammopathy of undetermined significance (MGUS), asymptomatic multip...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of one of the following plasmaproliferative diseases:
- Monoclonal gammopathy of undetermined significance (MGUS)
- Asymptomatic multiple myeloma
- Solitary plasmacytoma
- Other plasma cell dyscrasias
- Disease does not require therapy
- Willing to submit research samples for gene expression analysis and immunologic assessment
- PATIENT CHARACTERISTICS:
- Age
- Not specified
- Performance status
- Zubrod 0-2
- Life expectancy
- Not specified
- Hematopoietic
- Not specified
- Hepatic
- Not specified
- Renal
- Not specified
- Other
- No other malignancy within the past 2 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- No prior biologic therapy for this disease
- Chemotherapy
- No prior chemotherapy for this disease
- Endocrine therapy
- No prior endocrine therapy for this disease
- Radiotherapy
- No prior radiotherapy for this disease
- Surgery
- No prior surgery for this disease
- Other
- Prior or concurrent bisphosphonates allowed
Exclusion
Key Trial Info
Start Date :
June 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT00900263
Start Date
June 1 2002
Last Update
October 7 2016
Active Locations (69)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Cancer Center at Providence Hospital
Mobile, Alabama, United States, 36608
2
Highlands Oncology Group - Springdale
Bentonville, Arkansas, United States, 72712
3
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
4
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, United States, 90089-9181